Non-prescription anti-redness regimens effective in reducing facial redness in patients with rosacea, finds study

The treatment of rosacea is complicated as multiple pathogenic factors in play result in a myriad of clinical signs and symptoms including facial redness. The primary objective was to evaluate the efficacy and tolerability of a non-prescription anti-redness regimen in patients with rosacea. Thirty subjects with rosacea-induced facial erythema were enrolled in this single-site, monadic study. The test regimen consisted of a treatment serum, redness-reducing moisturizer, and sunscreen.

The test products are formulated with ingredients curated to address the multifactorial pathogenesis of facial redness. Investigator and subject self-assessment for efficacy and tolerability were performed at baseline, weeks 4 and 8. Non-invasive assessments for facial redness and skin hydration were conducted at all time points. Results: Investigator grading showed significant improvement in facial redness of 21% at week 4 and 32% at week 8. Skin's appearance improved as early as 4 weeks while at 8 weeks there was a statistically significant improvement in fine lines 15%, radiance/brightness 37%, tactile roughness 44%, visual roughness 41%, and 26% in overall appearance. Non-invasive assessments showed statistically significant improvement in skin hydration of 28% at week 4 and facial redness of 21% by week 8. No tolerability issues were identified by the investigator.

Patients with rosacea often turn to over-the-counter products to reduce facial redness and improve the skin's appearance. In this study, a cosmetic skincare regimen designed to reduce facial redness demonstrated efficacy and tolerability in subjects with rosacea.

Reference:

Farris PK, Gerstein FH, Baldwin HE, Draelos ZD. A Cosmetic Regimen Formulated to Address the Multi-Modal Pathogenesis of Rosacea Demonstrates Efficacy for Treating Facial Redness and Skin's Appearance. J Drugs Dermatol. 2024 Sep 1;23(9):757-763. doi: 10.36849/JDD.8460. PMID: 39231085.